…tical COVID (Haas et al. Lancet 2021; epublished 5 May 2021; www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2900947-8). The estimated prevalence of the UK variant (B.1.1.7) at the time of the study was 94.5% of samples, indicating that efficacy against the variant was comparable to what has been reported against the pandemic strain (D614G variant). The UK variant has been associated with a higher risk of mortality (hazard ratio 1.67) (Grint…

…et (www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html). The controversial recommendation states that an mRNA COVID-19 vaccine should be preferentially offered to individuals. The AstraZeneca COVID-19 vaccine may be offered to people aged >30 years only if the individual does not wish to wait for an mRNA vaccine. Individuals are advised to do their own be…

…care products Regulatory Agency (Williams S. The Scientist, 16 April 2021; www.the-scientist.com/news-opinion/blood-clot-risk-from-covid-19-higher-than-after-vaccines-study-68675). It should be noted that the thrombotic complications linked to COVID vaccination are, in part, a subset of CVT that occur in the setting of thrombocytopenia, a syndrome that has been labelled vaccine-induced prothrombotic immune thrombocytopenia (VIPIT, or VITT). The CD…